Opportunity to Invest in a Disruptive Tobacco Alternative
Tobacco use continues to be the leading cause of preventable death and disease around the world. Research shows that most smokers — nearly 70% — say they want to quit, making up an approximate 900 million consumers that are actively trying to change their habits and stop smoking. For even the heaviest and most stubborn of smokers, the innovative product offered by Quitta might be the solution. The company recently joined KapVista’s Ecosystem in their Seed raise of A$2,250,000.
There has been little innovation in Nicotine Replacement Therapies (NRTs) over 35 years – just 4 products – and even the best ones are just less than 10% effective. Patches and gum act too slowly to be truly effective, leading aspiring quitters back to cigarettes. Meanwhile, e-cigarettes have come under increased scrutiny and none have yet met safety thresholds for medicinal approvals.
Quitta's Solution - a fast-acting inhaled NRT
Quitta’s product is a nicotine “puffer” that delivers nicotine rapidly without combustion, heating or harmful chemicals.
Register interest in Quitta here.
Raising A$2,25M + target to exit to pharma <5 years
Valuation pre-money $6M
Double the efficacy of patches, and acts 3x faster than its closest competitor.
Projecting profit from year 3 of operations.
If you’d like to chat more about this opportunity, our Team will be more than happy to make an introduction. Register your interest in this email by clicking the button above or replying directly.
© 2020 KapVista